Literature DB >> 35001141

Combined overexpression of four transcription factors promotes effector T cell dedifferentiation toward early phenotypes.

Lijun Yan1,2, Yusheng Ou1,2, Shengfang Xia1,2, Jianqing Huang1,2, Wenfeng Zhang1,2, Hongwei Shao1,2, Han Shen1,2, Huaben Bo1,2, Changli Tao1,2, Jinquan Wang1,2, Fenglin Wu3,4.   

Abstract

Effector T cells, which are abundant but are short-lived after reinfusion into the body, are generally used for T-cell therapy, and antitumor immunity is typically not maintained over the long term. Genetic modification by early differentiated T cells and reinfusion has been shown to enhance antitumor immunity in vivo. This study overexpressed the characteristic transcription factors of differentiated early T cells by transfecting effector T cells with transcription factor recombinant lentivirus (S6 group: BCL6, EOMES, FOXP1, LEF1, TCF7, KLF7; S1 group: BCL6, EOMES, FOXP1, KLF7; S3 group: BCL6, EOMES, FOXP1, LEF1) to induce a sufficient number of effector T cells to dedifferentiate and optimize the transcription factor system. The results revealed that overexpression of early characteristic transcription factors in effector T cells upregulated the expression of early T cell differentiation markers (CCR7 and CD62L), with the S1 group having the highest expression level, while the rising trend of late differentiation marker (CD45RO) expression was suppressed. Moreover, the expression of early differentiation-related genes (ACTN1, CERS6, BCL2) was significantly increased, while the expression of late differentiation-related genes (KLRG-1) and effector function-related genes (GNLY, GZMB, PRF1) was significantly decreased; this difference in expression was more significant in the S1 group than in the other two experimental groups. The antiapoptotic ability of each experimental group was significantly enhanced, while the secretion ability of TNF-α and IFN-γ was weakened, with the effector cytokine secretion ability of the S1 group being the weakest. Transcriptomic analysis showed that the gene expression profile of each experimental group was significantly different from that of the control group, with differences in the gene expression pattern and number of differentially expressed genes in the S1 group compared with the other two experimental groups. The differentially expressed gene enrichment pathways were basically related to the cell cycle, cell division, and immune function. In conclusion, overexpression of early characteristic transcription factors in effector T cells induces their dedifferentiation, and induction of dedifferentiation by the S1 group may be more effective.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Dedifferentiation; T lymphocytes; Transcription factor

Mesh:

Substances:

Year:  2022        PMID: 35001141     DOI: 10.1007/s00251-021-01248-z

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  32 in total

Review 1.  Molecular regulation of effector and memory T cell differentiation.

Authors:  John T Chang; E John Wherry; Ananda W Goldrath
Journal:  Nat Immunol       Date:  2014-12       Impact factor: 25.606

2.  Enzymatic assembly of DNA molecules up to several hundred kilobases.

Authors:  Daniel G Gibson; Lei Young; Ray-Yuan Chuang; J Craig Venter; Clyde A Hutchison; Hamilton O Smith
Journal:  Nat Methods       Date:  2009-04-12       Impact factor: 28.547

Review 3.  Paths to stemness: building the ultimate antitumour T cell.

Authors:  Luca Gattinoni; Christopher A Klebanoff; Nicholas P Restifo
Journal:  Nat Rev Cancer       Date:  2012-09-21       Impact factor: 60.716

Review 4.  Human memory T cells: generation, compartmentalization and homeostasis.

Authors:  Donna L Farber; Naomi A Yudanin; Nicholas P Restifo
Journal:  Nat Rev Immunol       Date:  2013-12-13       Impact factor: 53.106

5.  Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8+ T cell stemness and antitumor immunity.

Authors:  Dalton Hermans; Sanjivan Gautam; Juan C García-Cañaveras; Daniel Gromer; Suman Mitra; Rosanne Spolski; Peng Li; Stephen Christensen; Rosa Nguyen; Jian-Xin Lin; Jangsuk Oh; Ning Du; Sharon Veenbergen; Jessica Fioravanti; Risa Ebina-Shibuya; Christopher Bleck; Leonard M Neckers; Joshua D Rabinowitz; Luca Gattinoni; Warren J Leonard
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-02       Impact factor: 11.205

6.  Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells.

Authors:  Luca Gattinoni; Christopher A Klebanoff; Douglas C Palmer; Claudia Wrzesinski; Keith Kerstann; Zhiya Yu; Steven E Finkelstein; Marc R Theoret; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Clin Invest       Date:  2005-06       Impact factor: 14.808

Review 7.  Telomerase and primary T cells: biology and immortalization for adoptive immunotherapy.

Authors:  Eugene V Barsov
Journal:  Immunotherapy       Date:  2011-03       Impact factor: 4.196

8.  A human memory T cell subset with stem cell-like properties.

Authors:  Luca Gattinoni; Enrico Lugli; Yun Ji; Zoltan Pos; Chrystal M Paulos; Máire F Quigley; Jorge R Almeida; Emma Gostick; Zhiya Yu; Carmine Carpenito; Ena Wang; Daniel C Douek; David A Price; Carl H June; Francesco M Marincola; Mario Roederer; Nicholas P Restifo
Journal:  Nat Med       Date:  2011-09-18       Impact factor: 53.440

9.  Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells.

Authors:  Luca Gattinoni; Xiao-Song Zhong; Douglas C Palmer; Yun Ji; Christian S Hinrichs; Zhiya Yu; Claudia Wrzesinski; Andrea Boni; Lydie Cassard; Lindsay M Garvin; Chrystal M Paulos; Pawel Muranski; Nicholas P Restifo
Journal:  Nat Med       Date:  2009-06-14       Impact factor: 53.440

10.  Simplified production and concentration of lentiviral vectors to achieve high transduction in primary human T cells.

Authors:  Adam P Cribbs; Alan Kennedy; Bernard Gregory; Fionula M Brennan
Journal:  BMC Biotechnol       Date:  2013-11-12       Impact factor: 2.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.